The Money Blind: How to Stop Industry Bias in Biomedical Science, Without Violating the First Amendment

31 Pages Posted: 1 Sep 2013

Date Written: 2011

Abstract

The pharmaceutical and medical device industries use billions of dollars to support the biomedical science that physicians, regulators, and patients use to make healthcare decisions—the decisions that drive an increasingly large portion of the American economy. Compelling evidence suggests that this industry money buys favorable results, biasing the outcomes of scientific research. Current efforts to manage the problem, including disclosure mandates and peer reviews, are ineffective. A blinding mechanism, operating through an intermediary such as the National Institutes of Health, could instead be developed to allow industry support of science without allowing undue influence. If the editors of biomedical journals fail to mandate that industry funders utilize such a solution, the federal government has several regulatory levers available, including conditioning federal funding and direct regulation, both of which could be done without violating the First Amendment.

Keywords: biomedical science, bias, healthcare decisions, disclosure, blinding mechanism, regulation, funding, First Amendment

Suggested Citation

Robertson, Christopher T., The Money Blind: How to Stop Industry Bias in Biomedical Science, Without Violating the First Amendment (2011). 37 American Journal of Law and Medicine 358 (2011), Arizona Legal Studies Discussion Paper No. 13-42, Available at SSRN: https://ssrn.com/abstract=2318616

Christopher T. Robertson (Contact Author)

Boston University ( email )

765 Commonwealth Avenue
Boston, MA 02215
United States
6179100649 (Phone)
02215 (Fax)

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
119
Abstract Views
1,689
Rank
440,219
PlumX Metrics